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Summary 
Free peptide has been found to inhibit cytotoxic T lymphocyte (CTL) activity, and veto cells 
bearing peptide-major histocompatibility complex (MHC) complexes have been found to in- 
activate CTL, but the two phenomena have not been connected. Here we show that a com- 
mon mechanism ay apply to both. CD8 + CTL lines or clones specific for a determinant of 
the human immunodeficiency virus (HIV) 1 IIIB envelope protein gp160, P18IIIB, are inhib- 
ited by as little as 10 min exposure to the minimal 10-mer peptide, 1-10, within P18IIIB, free 
in solution, in contrast to peptide already bound to antigen-presenting cells (APC), which does 
not inhibit. Several lines of evidence suggest that the peptide must be processed and presented 
by H-2D a on the CTL itself to the specific T cell receptor (TCR) to be inhibitory. The inhibi- 
tion was not killing, in that CTL did not kill SlCr-labeled sister CTL in the presence of free 
peptide, and in mixing experiments with CTL lines of different specificities restricted by the 
same MHC molecule, D a, the presence of free peptide recognized by one CTL line did not in- 
hibit the activity of the other CTL line that could present he peptide. Also, partial recovery of 
activity could be elicited by restimulation with cell-bound peptide, supporting the conclusion 
that neither fratricide nor suicide (apoptosis) was involved. The classic veto phenomenon was 
ruled out by failure of peptide-bearing CTL to inactivate others. Using pairs of CTL lines of 
differing specificity but similar MHC restriction, each pulsed with the peptide for which the 
other is specific, we showed that the minimal requirement is simultaneous engagement of the 
TCR and class I MHC molecules of the same cell. This could occur in single cells or pairs of 
cells presenting peptide to each other. Thus, mechanistically the inhibition is analogous to 
veto, and might be called self-veto. As a clue to a possible mechanism, we found that free 1-10 
peptide induced apparent downregulation of expression of specific TCR as well as interleukin 2
receptor, CD69, lymphocyte function-associated antigen 1, and CD8. This self-veto effect also has 
implications for in vivo immunization and mechanisms of viral escape from CTL immunity. 
T he TCR of CD8 + class I MHC molecule-restricted cytotoxic T lymphocytes (CTL) binds a processed an- 
tigenic peptide, usually composed of 8-10 amino acids, fit- 
ted within the groove of a class I MHC molecule situated 
on the cell surface (1). Although peptide added free in solu- 
tion may bind to the class I MHC molecule of the effector 
CTL, lysis of peptide-coated CTL by other CTL has been 
reported unlikely (2-4), probably because CTL are resistant 
to their own cytolytic mediators. Nevertheless, we found 
that a free peptide of optimal size (I-10: RGPGRAFVTI  
from HIV-1 gp160 envelope glycoprotein) (5, 6) almost 
completely blocked the specific CTL activity toward tar- 
gets presensitized with the same peptide when added in so- 
lution during the 4-6 h 51Cr elease assay. 
Several recent papers have described similar inhibitory 
phenomena by free antigenic peptide (7-11), but the 
mechanism of this inhibition is still controversial. Some pa- 
pers suggest self-destruction (suicide) (8, 9, 12), some argue 
CTL-CTL  killing (fratricide) (13), and some indicate a 
pronounced but transient inhibition or inactivation (an- 
ergy) (14). Also, as Su et al. (13) point out, the require- 
ments for killing may be different from those for anergy. A 
possibly related phenomenon was seen earlier for CD4 + 
MHC class II-restricted Th cells, in which exposure of T 
cell clones to high concentrations ofpeptide for >6 h led 
to an anergic state lasting at least 7 d, although the cells 
were not killed because they could still respond to IL-2 
(15-17). In this case, peptide had to be presented on class II 
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MHC molecules, but did not require APC other than the 
human class II MHC-posi t ive T cells themselves. How-  
ever, subsequent studies showed that such anergy induced 
by antigen presented on T cells was not due to lack of  co- 
stimulation (18), and so the mechanism was distinct from 
that of  anergy induced by ant igen-MHC complexes in the 
absence ofcostimulation (19, 20). 
Another situation in which CD8 + CTL are inactivated 
but not always killed is termed the veto phenomenon (11, 
21-24). The veto cell is a cell expressing the pept ide-  
MHC complex recognized by the receptor of  the CTL, 
which inactivates the CTL that targets it. Another CD8 § 
cell is the most effective type of  veto cell, but the veto phe- 
nomenon does not require engagement of  the antigen-spe- 
cific TCR of  the veto cell, only its class I MHC molecules. 
Recent studies have shown that the CD8 molecule of  the 
veto cell plays a role by binding the o~3 domain of  the 
MHC class I molecule o f  the CTL being vetoed (24). This 
phenomenon has been studied largely in cases of  CTL spe- 
cific for histocompatibility antigens (22), but recently cells 
presenting defined peptides have been shown to veto (11). 
However, in contrast o the studies of  free pepude inhibi- 
tion of  CTL, CTL clones are resistant to the veto phenom- 
enon (23). Thus, no connection has been made previously 
between the two phenomena. 
In this study, we show that the inhibition of  CTL is ini- 
tiated by the binding of  antigenic peptide for which the 
CTL as specific to the MHC molecules on the CTL's own 
surface, and is not caused by either the peptide presented 
only on other cells including saster CTL, or by direct inter- 
acnon of  the TCR with free peptide. Using pairs of  CTL 
lines of  differing specificity but similar MHC restriction, 
each pulsed with the peptlde for which the other is specific, 
we show that the minimal requirement is simultaneous en- 
gagement of  the TCR and class I MHC molecules of  the 
same cell. The transient anergy is associated with downreg- 
ulation of  the TCR and several accessory cell surface mole- 
cules. 
This mechanism of  inhibition characterized here as remi- 
niscent of  the veto mechamsm. However, it is not simply 
the classic veto phenomenon, because CTL presenting the 
peptide to other CTL do not inhibit them. We suggest hat 
indeed the inhibition by free pepude is analogous at the 
molecular level to the veto phenomenon, but that CTL 
clones require a stronger signal through their MHC class l 
molecules, using a TCR rather than simply CD8 interac- 
tion with the c~3 domain. Thus, free peptide inhibition of  
CTL clones may be considered a process of  "self-veto." 
This self-veto phenomenon may be important not only for 
in vitro studies, but also in vivo for its possible ffect on vi- 
ral persistence and CTL inactivation by viral products. 
Materials and Methods 
Animals. BALB/c (D d, L d, K d) trace were obtained from 
Charles River Japan Inc. (Tokyo, Japan) and B10.A (D a, L d, K k) 
from Sankyo Laboratory Inc. (Tokyo, Japan). Mice were used at 
6-12 wk of age. 
CTL Lines and Clones. The CTL hne (LINE-IIIB) and clones 
specific for the HIV-1 envelope protein of the lllB isolate 
(gp160IIIB) were generated as described (25). Both the gpl60lllB- 
specific CTL line and the clones were restricted by the D a class I 
MHC molecule and were specific for an immunodominant 
epltope P18IIIB (RIQRGPGRAFVTIGK). The mlmmal acnve 
peptide was shown to be the 10-mer, P18-l-10 (5, 6, 26). The 
CTL line (LINE-MN) specific for the HIV-1 envelope of the 
MN isolate (gp160MN) was obtained from vMN (gp160MN- 
expressing recombinant vaccima virus)-immune BALB/c spleen 
cells (27). It was stimulated with P18MN (RIHIGPGRAFYT- 
TKN)-pulsed irradiated syngenelc spleen cells and wath rat ConA 
supernatant added on the second ay and maintained by biweekly 
repetitive stimulation. 
Synthetic Peptides. The peptides are named according to the 
last amino acid residue and the length, except for the onginal 
P18IIIB and P18MN peptides. Peptides were synthesized and pu- 
rified as described previously (25-27). 
mAbs. The following mAbs were used: ann-CD4 (RL172.4) 
(28) for deplenng P18IIIB-speclfic I-Aa-resmcted (29) CD4 + Th 
cell hne (HT-4) (6) and ant~-K k (30) for depleting B10.A spleen 
cells with rabbit C (Cederlane Laboratones Ltd., Homby, On- 
tario, Canada); FITC-labeled anti-CD3 (2C1l [31]), anti-lL- 
2Rc~ (32), anu-CD69 (33), or anti-V[3-8.1 (34), anti-D a (r do- 
mare) (34-2-12 [35]), anu-L a (30-5-7 [36]), and anti-K a (31-3-4 
[36]) for cell surface staining. 
Inhibition of Serum Actiwty upith Angiotensin-convertmg Enzyme 
(ACE) Inhibitor. The ACE (EC3.4.15.1 peptidyl/dipeptide hy- 
drolase)-specific inhahitor captopnl (Sigma Chermcal Co., St. 
Louis, MO) was dissolved in PBS at 100 p,M and added to the 
culture at 10 -5 M 30 rain before mLxmg with the inhibitory pep- 
tide. 
CTL Assay. Cytotoxicity was assessed in a standard 5-h SICr 
release assay as described previously (37), with StCr-labeled tar- 
gets, as indicated m the figure legends. SEM oftriphcate cultures 
was always <5% (and often <3%) of the mean. 
FACS ~ Analysis. For direct one-color staining to determine 
the effect of free peptide treatment of the gp160IllB-specific 
CTL lines or clones on their surface molecule expression, lff ~ 
cells were incubated at 37~ for 1 h with free [-10 and then 
washed three times with RPMI 1640 to remove free peptide. 
Then, 1 p.g of each indicated FITC-labeled antibody was added 
to the cell pellet for a 40-rain incubation at 4~ All reagents 
were pretitered and used in amounts known to be saturating on 
positive controls. The cells were washed three umes and resus- 
pended at 106 cells/0.5 ml in PBS/BSA/azlde for analysis by 
FACScan | analyzer (Becton Dickinson Immunochemastry S s- 
tems, Mountain View, CA). Dead and damaged cells were ex- 
cluded from the analysis by propidium Iodide gating. 
Results 
Free Peptides Inhibit CTL  Activities in a Dose-dependem 
Manner. The minimal epitope of  CD8 + CTL lines or 
clones specific for an immunodominant determinant of  the 
HIV-1 IIIB envelope protein gp160, 18IIIB (315-329) 
(R IQRGPGRAFVT IGK) ,  presented by the murine class I 
MHC molecule H-2D d, has been identified as a 10-mer 
peptide, 1-10 (RGPGRAFVT I )  (5, 6, 26). We have no- 
uced that we could not show a clear concentration depen- 
dence when the mimmal size free 1-10 was added together 
with S~Cr-labeled fibroblast argets during the 4-h assay, al- 
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though the longer peptide, 18IIIB, produced a normal ti- 
tration curve (Fig. 1 A). As a possible explanation, when 
we used peptide-pulsed targets, we observed that free 1-10 
strongly inhibited CTL activity even at very low concen- 
trations, whereas the longer peptide, 18IIIB, inhibited the 
activity only at high concentrations (Fig. 1 A). Similarly, 
high concentrations of free 18IIIB showed some inhibition 
when used with the unpulsed fibroblast argets. Similar re- 
suits were obtained in five other experiments, including 
one with 1-10-pulsed targets. Thus, inhibition by free 1-10 
superimposed on sensitization o f  targets by 1-10 led to a 
relatively flat net dose-response curve over a wide range, 
with less net killing than was seen with the longer peptide. 
Free peptide inhibition could also be observed in another 
system, using a different epitope (AH2-I9: residues 39-47 
from the HIV-1 reverse transcriptase r stricted by the K k 
MHC molecule [data not shown]). These results suggested 
that free epitopic peptides from the virus may inhibit spe- 
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cific CTL activity against virus-infected targets, and this 
may be another mechanism of  virus-specific CTL inactiva- 
tion in vivo. A number of  the experiments detailed below 
were carried out with both the HIV reverse transcriptase 
and envelope peptides with similar results, but for simplic- 
ity only the envelope peptide experiments are shown. 
Titration and Kinetics of 1-10 Treatment for CTL  Inhibi- 
tion. To further investigate the mechanism o f  the inhibi- 
tion, we pretreated the CTL line or clones with various 
concentrations of I-10 for 1 h in the absence of  targets, and 
then added these cells to the assay culture after complete 
removal of  the free peptide. Profound reduction of  CTL 
activity was observed when 1-10-specific CTL lines or 
clones were cocultured briefly with the free minimal pep- 
tide 1-10 at >1 v,M, and half-maximal inhibition was 
achieved at between 0.01 and 0.1 I~M peptide for only 1 h 
(data not shown). Surprisingly, <10-min  pretreatment 
with 1 I~M of  I-10 appeared to be sutticient to induce inhi- 
bition (Fig. 1 B). Shorter times could not be investigated 
because of  the time required for centrifugation and wash- 
ing. In contrast, although 1 I~M of  the 15-mer peptide 
18IIIB showed some inhibitory activity with 1-h pretreat- 
ment (Fig. 1 B), >2 h of  treatment was necessary to gener- 
ate strong inhibition (Fig. 2 A and data not shown). 
Requirement for Peptide Processing. The inhibition could 
not be observed when 1-10 was presented to the CTL in an 
already ceU-associated form, either 1-10-pulsed BALB/c.3T3 
fibroblast (Nee*I-10) or endogenously synthesized in a 
gp160-transfected BALB/c.3T3 flbroblast (15-12) (data 
not shown and see below). These results suggested that 
some processing steps are required for 18111]3 to be inhibi- 
Figure 1. (A) Free epitopic peptides inhibit CTL activity in a dose- 
dependent manner. Either 5 X 103 untreated SiCr-labeled BALB/c.3T3 
fibroblast targets (O-O, [D-C]) or an equal number of P18lllB-prepulsed 
SlCr-labeled BALB/c.3T3 target cells ( 00 ,  I t  ) were incubated with 
5 X 104 cells ofa P18IIIB-specific CTL line (LINE-IIIB) in the presence 
of various amounts of free antigenic peptides (P181IIB [[~O, i - i  ] or 
1-10 [OgD, 0-0]) in 96-well round-bottom icrotiter plates during the 
4 h assay. (B) Kinetics of 1-10 treatment for CTL inhibition. 106/m1 of 
LINE-IIIB cells were incubated with 1 p,M 1-10 for various times at 37~ 
in complete T-cell medium (CTM) ~ (25) and washed three times. Then 
5 • 104 treated LINE-IIIB cells were added to 5 • 10 3 of S~Cr-labeled 
P1811IB-prepulsed targets for 4 h. SEM of triplicate cultures was always 
<5% of the mean. 
1 Abbreviations u ed in this paper: CTM, complete T-cell medium. 
Figure 2. CTL inhibition by free peptide requires processing and pre- 
sentation of peptide by class I MHC molecules. (A) Captopril abrogates 
CTL inhibition by P18IIIB. 106/ml LINE-IIIB were incubated with 10 -5 
M captopril, a dipeptidase inhibitor that inhibits processing of P18IIIB to 
1-10 (26), together with 1 p~M P18IIIB or 1-10 overnight. Then the CTL 
were washed three times, and 5 • 10 4 treated LINE-IIIB cells were 
added to 5 X 103 SlCr-labeled P18IIIB-prepulsed targets for 4 h. (B)Ef- 
fect of coculturing with competitor peptide during 4-h CTL assay. 5 X 
103 P18IIlB-prepulsed 51Cr-labeled BALB/c.3T3 fibroblast targets were 
incubated with 5 X 104 P181IIB-specific LINE-IIIB cells at the indicated 
concentrations of competitor peptide together with (0-0) or without 
(O-O) 0.1 p,M 1-10 during the 4-h assay. SEM of triplicate cultures was 
always <5% of the mean. 
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tory, in contrast o 1-10, which may bind directly to the 
surface MHC molecules of  the CTL. To confirm this in- 
terpretation, we added the dipeptidase inhibitor captopril, 
which inhibits serum processing of  18IIIB to 1-10 (26), to- 
gether with either 18IIIB or 1-10 in an overnight culture 
with the CTL line, and found that captopril could abrogate 
the inhibitory activity of  18IIIB but not 1-10 (Fig. 2 A). 
These findings were reproducible in two additional experi- 
ments. Also, since captopril did not affect 1-10 inhibition of  
CTL activity, it should not be acting at other steps, such as 
peptide binding to MHC.  In addition, inhibition by 
18IIIB, but not by 1-10, requires the presence of  FCS (data 
not shown). Thus, proteolysis of  the 15-mer peptide is 
necessary for it to inhibit. Also consistent with presentation 
of processed peptide by D a as a requirement for inhibition, 
we found that treatment of  CTL with mAbs pecific for D a 
partially prevented the inhibition (data not shown). 
CTL Inhibition Can Be Partially Abrogated by Competitive 
Peptide. To test whether inhibition required binding of  
the free 1-10 to the TCR on the CTL and not just to the 
MHC molecule, we synthesized 1-10 (325(V-Y)) with a 
single substitution at position 325, which we have identi- 
fied as the major site for interacting with the TCR (25, 27). 
We have previously demonstrated that HIV-1 IIIB--specific 
CTL tend to see aliphatic amino acids at position 325, 
whereas MN-specif ic CTL see aromatic or cyclic amino 
acids at this position (38). This substituted peptide 1-10 
(325(V-Y)) could not be recognized by IIIB-specific CTL 
at all, although it binds to D d because it can he seen by 
MN-specific CTL with D a (data not shown). Also, studies 
with sequentially added peptides indicated that the substi- 
tuted peptide was not an antagonist (39-41) (data not 
shown). Thus, the peptide cannot interact with the TCR 
of  IIIB-specific CTL despite its binding to the D d class I 
MHC molecule. As shown in Fig. 2 B, peptide 1-10 
(325(V-Y)) did not itself inhibit, but competitively blocked 
the inhibition induced by 1-10 in a dose-dependent man- 
ner during the 4-h CTL assay (Fig. 2 B). Thus, peptide 
must bind to both the MHC molecule and the TCR on 
the CTL to inhibit. Also, since the modified peptide can- 
not compete for binding to the TCR., this result also con- 
finns that inhibition is mediated by pept ide -MHC com- 
plexes and not direct binding of  the peptide to the TC1K. 
I-lO-pulsed T Cells Did Not Inhibit CTL Activity. Since 
free peptide had to bind to the appropriate class I MHC 
molecule and be presented to the TCR of  the CTL being 
inhibited, we asked why peptide already bound to D d on 
fibroblasts did not inhibit. Perhaps the peptide had to be 
presented on another type of  cell. Therefore, we pulsed 
1-10 onto a whole-spleen cell population, chosen to have 
the same D a molecule but a different H-2K molecule so 
that the cells could be depleted afterwards. We did not ob- 
serve any inhibition when the CTL were cocultured for 
1 h with irradiated B10.A (D d and K k) spleen cells 
prepulsed with 1-10 and then treated with anti-K k mAb 
and rabbit C to remove B10.A cells (Fig. 3 A). Some ap- 
parent cold-target inhibition by the peptide-pulsed B10.A 
cells is eliminated when these are removed. These results 
Figure 3. Inabihty of spleen cells and other T cells to mediate peptide 
inhibition of CTL lines. (A) Effect of 1-10-pulsed B10.A spleen cells on 
LINE-IIIB inhibition. 5 • 106/ml B10.A (D a and K k) spleen cells (APC) 
were incubated with 1 btM 1-10 for 1 h in CTM (25), 3,300 rad irradi- 
ated, washed three times, and mixed with 5 • 104 IllB-specific CTL line 
cells for another 1 h. The mixed cells were then treated with anti-K k 
mAb and rabbit C to deplete B10.A cells and cocultured with 5 • 103 
SICr-labeled gp160-expressing BALB/c3T3 fibroblast (15-12) targets for 
4 h. (B) Effect ofcoculturing with 1-10-pulsed T cells on CTL inhibition. 
106/ii11 LINE-IIIB were cocultured with an equal number of CD8 § 
LINE-IIIB prepulsed for 1 h with I ~M 1-10 or MNT10, or with the 
P181IIB-specific CD4 + helper T cell line, HT-4, prepulsed with 1 ~M 
1-10 for 1 h. Where indicated, the mixed cells were then treated with 
anti-CD4 mAb (RL174) and rabbit C to deplete the CD4 + HT-4 line. 
Then the effector cells were cocultured with 5 • 103SlCr-labeled 
P18IllB-prepulsed targets for 4 h. SEM of triplicate cultures was always 
<5% of the mean. 
were reproducible in three experiments. These data 
strongly indicated that the free peptide 1-10 does not work 
via binding to APC contamination i  the CTL line, but 
only by binding to the CTL themselves. These data also ar- 
gue against inhibition by veto cells in the spleen, which 
should inhibit the CTL to which they present peptide. 
Failure to see such a veto phenomenon is consistent with 
the resistance of  CTL clones to veto (23). 
If the free peptide requires processing so that it can bind 
to MHC molecules, but does not act when bound to other 
cells, it may have to be presented by T cells to inhibit. 
Therefore, we tested the effect ofpresention by other CD4 + 
or CD8 + T cells. Taking advantage of  the Da-expressing 
CD4 + helper T cell line, HT-4  (6), 1-10-specific CTL line 
(LINE-IIIB) cells were mixed with an equal number of  
1-10-pulsed HT-4  or an equal number of 1-10-pulsed 
LINE-I I IB cells before being added to the 51Cr-labeled 
Neo*l-10 targets for the 4-h assay culture. In contrast o 
unpulsed HT-4,  1-10--pulsed HT-4  significantly inhibited 
the activity of  LINE-I I IB,  whereas 1-10-pulsed CD8 + 
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CTL of  the same LINE-I I IB did not (Fig. 3 B). We have 
found that LINE-I I IB did efficiently kill 51Cr-labeled HT-4 
cells when pulsed with 1-10, whereas they did not lyse 
SlCr-labeled 1-10-pulsed LINE-I I IB as targets (data not 
shown). Thus, we speculated that 1-10-pulsed HT-4 prob- 
ably acted as cold target inhibitors in the assay culture. 
Therefore, we depleted the culture of  1-10-pulsed HT-4 
cells by treatment with rat anti-mouse CD4 mAb (R.L174) 
plus rabbit C after a 2-h incubation with LINE-I I IB, and 
then added the residual LINE-I I IB to the assay system for 
an additional 4 h. Depletion of  1-10-pulsed HT-4 cells 
completely abrogated the inhibition. This result, repro- 
duced in two additional experiments, uggests that the pep- 
tide, 1-10, does not inhibit specific CD8 + CTL when pre- 
sented by their fellow CD8 + T cells, and the inhibition by 
1-10-pulsed CD4 § T cells appears to be by a different 
mechanism, cold-target inhibition, which does not explain 
the effect of  free peptide on CTL. This result also excludes 
a classic veto mechanism, in which CD8 § cells presenting 
peptide to the TCR ofa  CTL inhibit it (11, 21-23). 
Fratricide May Not Be the Cause of Inhibition. These re- 
sults demonstrate that free antigenic peptide must bind to 
the MHC molecule on the surface of  effector CTL to 
downregulate heir cytolytic activity. To distinguish whether 
the mechanism of  inhibition was CTL fratricide, suicide, or 
anergy induced when the TCP, interacts with a peptide- 
MHC complex on the surface of  the CTL itself, we 51Cr 
labeled some of the same CTL line as targets and found that 
they did not kill each other in the presence of  free peptide 
(data not shown). Moreover, in mixing experiments with 
two non-cross-reactive CD8 + CTL lines (LINE-IIIB and 
L INE-MN) specific for two homologous peptides, 18IIIB 
(or 1-10) and 18MN (or MNT10) from different HIV-1 
isolates, both presented by the same MHC molecule, 
H-2D d, we found that the presence of  free peptide recog- 
nized by one CTL line but able to bind to H-2D a on both 
CTL lines did not inhibit the cytolytic activity of  the other 
syngeneic CTL line for its targets, as would be expected 
if the mechanism had been fratricide (Fig. 4, reproduced 
in three additional experiments). Furthermore, MNT10-  
prepulsed LINE-I I IB was not inhibited at all when cocul- 
tured with L INE-MN and, conversely, 1-10-prepulsed 
L INE-MN was not inhibited when cocultured with LINE- 
IIIB (see Fig. 5). Thus, the mechanism of CTL inhibition 
by the free epitopic peptide appears not to be fratricide, in- 
hibition by one T cell of  another T cell presenting the spe- 
cific peptide, or the release of  inhibitory cytokines. Rather, 
it appears that the peptide must be presented on the T cell's 
own MHC molecules, to the cell's own TCR specific for 
that pept ide-MHC complex. 
Dual Engagement Requirement. The possibility remained 
that simultaneous occupancy of  both the TCR and MHC 
molecule on the CTL was all that was required, so that two 
CTL lines specific for different peptides on the same MHC 
molecule could inhibit each other if each was pulsed with 
the peptide for which the other CTL was specific and they 
were washed and mixed. This experiment differs from the 
previous one in that the CTL presenting one peptide in its 
883 Takahashi et al. 
Figure 4. Fratricide is not the cause of inhibition by free peptide. 5 )< 
104 treated cells of LINE-IIIB and/or LINE-MN were added to 5 • 10 3 
StCr-labeled P18llIB-prepulsed targets (A) or P18MN-prepulsed targets 
(/3) in the presence of either 1 ~M of See P18IIIB (I-10) or an equal 
amount of free P18MN (MNT10) for 4 h. SEM of triplicate cultures was 
always <5% of the mean. 
MHC molecule also can engage its TCP, with the peptide- 
MHC on the other T cell at the same time. To test this 
possibility, we mixed L INE-MN pulsed with 1-10 and 
LINE-I I IB pulsed with MNT10 and found that both were 
inhibited (Fig. 5), tested on their respective targets. Only 
this configuration of  pulsed cells showed inhibition. This 
inhibition in trans appears less efficient than in cis, that is, 
when the TCR was engaging the pept ide-MHC complex 
on the same cell, but was reproducible and statistically sig- 
nificant. In eight inhibition experiments in four indepen- 
dent studies similar to the one shown in Fig. 5, the mean 
percentage of inhibition was 40.3 + 2.69% (P <0.001 by 
Student's t test). Thus, the mechanism of  inhibition appears 
to require that both the MHC molecules and the TCP,.s of  
the CTL be engaged simultaneously ("dual engagement"), 
either on the same cell or in a conjugate between two r 
more cells. This dual engagement mechanism is reminis- 
cent of, but distinct from, the veto process (see Discussion). 
I-lO-treated CTL Activity Could Be Partially Restored by 
Restimulation. If  the mechanism of  inhibition were apop- 
tosis of  CTL, cytotoxic activity should not be recovered by 
restimulation, whereas if it were anergy, activity might be 
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Figure 5. Dual engagement may be the cause ofinkibition by free pep- 
tide. 2 • 106/ml non-cross-reactive CTL lines, LINE-IIIB and LINE-MN 
(P18MN-specific CTL line), were pretreated with either 1 ~M 1-10 or 
MNT10 for 1 h at 37~ After b ing washed three times, 5 • 104 treated 
cells of LINE-1IIB and/or LINE-MN were added to5 • 103 SlCr-labeled 
1-10-prepulsed targets (A) or MNT10-prepulsed targets (/3) for 4 h. SEM 
of triplicate cultures was always <5% of the mean. 
clone RT-3  (not shown) treated with 1 l iM  1-10 for 1 h 
could be restored to almost 80% of  their original activities 
by  restimulation with 1-10-expressing BALB/c  fibroblasts 
even 2 d after the free peptide treatment (reproducible in 
three experiments). Even if the cells were pretreated with 
1-10 for a full 24 h and then restimulated with the gp160 
transfectant 15-12, 83% of  the activity could be recovered 
(data not  shown). This result suggests that the major mech-  
anism of  inhibit ion is temporary self-inactivation (anergy) 
rather than apoptosis (suicide). We also could not  detect 
any DNA ladders in the CTL  treated with 1-10 for 2 h and 
Figure 6, CTL inhibited by free 1-10 can be partiaUy restored by re- 
stimulation with 1-10-expressing cells. 4 • 106/ml LINE-IIIB were 
treated with 1 p.M off-10 for 1 h and washed three times. After 1 or 2 d 
further incubation at 106/1Ill, treated cells were restimulated with 10S/ml 
mitomycin C-treated 1-10-expressing syngeneic BALB/c 3T3 fibroblasts 
together with IL-2 for another 5 d in a 24-well culture plate, harvested, 
and tested for their cytolytic activities against 5 X t03 SlCr-labeled 
Pl8IllB-prepulsed targets at n E/T ratio of20:l. SEM of triplicate cul- 
tures was always <5% of the mean. 
Figure 7. Downregulation f surface markers on the CTL treated with 
free 1-10. 106 cells were incubated for 1 h with free 1-10 and washed 
three times. Then 1 ~g of the indicated FITC-labeled antibody was 
added to the cell pellet for a 40-min incubation at 4~ The cells were 
washed three times andresuspended at 106 cells/0.5 ml in PBS/BSA/ 
azide for analysis by FACScan | 
then cultured without  peptide for an additional 24 h, or 
pulsed with 1-10 for a full 24 h (data not shown). 
Downregulation fSurface Markers on the CTL Treated with 
Free 1-10. As a clue to a possible inhibitory mechanism, 
we found that free 1-10 induced apparent downregulat ion 
of  expression of  specific TCR (V[38.1 on clone RT-2  or 
ILT-3 [Takahashi, H., and Y. Nakagawa, unpubl ished ob- 
servation]) as well as CD3,  I L -2R (ee, and [3 not  shown), 
CD69 (activated T cell marker), LFA-1 (not shown), and 
CD8 (Fig. 7). However,  class I MHC molecules uch as D a 
(Fig. 7), K a, or L a (data not  shown) did not  show any 
downmodulat ion  on the 1-10-treated CTL.  The same pat- 
tern of  downregulat ion was seen in five independent  ex- 
periments, as well as one in which the cells were main-  
tained in suspension (albeit to a slightly lesser extent). It 
was also observed after 24 h of  exposure to 1-10, and the 
expression remained partially downregulated 24 h after a 1-h 
exposure (data not shown). The lack of effect on class I MHC 
molecules uggests that the FACS | analysis results are not 
merely caused by downsizing of  the cells or a generalized 
effect on  all surface molecules. Thus, the inhibit ion of  CTL  
activity is concurrent with a downmodulat ion  of  surface 
activation markers and specific TCR,  the latter resembling 
that reported for CD4 + class II MHC-restr ic ted T cells ex- 
posed to high concentrations of specific peptide (17). 
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Discuss ion 
In this study, we found that exposure of CD8 + CTL to a 
peptide corresponding to the minimal epitope, free in solu- 
tion, leads to strong inhibition of the cytolytic activity of 
the epitope-specific CTL. Our data suggest that this effect 
requires dual engagement ofTCP,. and MHC molecules on 
the same T cell and involves downregulation of TCR. and 
several other surface molecules without cell death. Al- 
though shown to be distinct from the classic veto mecha- 
nism (21-24), which does not act on long-term CTL fines 
and clones in vitro, the dual engagement requirement is
nevertheless rather analogous to the veto mechanism on a 
molecular level, so that the inhibition by free peptide may 
be considered a self-veto process, as discussed below. 
Several papers have reported that free pitopic peptide 
can inhibit the specific activities of CD8 + CTL (7-11). 
However, the mechanism of the inhibitaon is still contro- 
versial, and previous tudies have not examined a dual en- 
gagement requirement. Suet  al. (13) concluded that the 
mechanism of inhibitaon by fr~e cognate peptide is "fratri- 
cide" rather than "suicide" (8, 9, 12) based on experiments 
using CTL isolated with the microdrop separation tech- 
nique using gel agarose. However, although no killing was 
observed in the isolated cells in microdrops, functional an- 
ergy could not be tested. Thus, there is no real discrepancy 
with our study, in which we observe anergy but not kill- 
ing, and in which the process appears to be able to occur in 
single cells. LaSalle et al. (42) observed that anergy required 
cell contact when peptides presented by class II MHC mol- 
ecules were used, but it is not clear that the mechanism is
the same as described here for class I MHC presentation. If,
as our data suggest, either a single cell or two-cell mecha- 
nism can occur, one or the other may predominate de- 
pending on cell density and peptide concentration. Thus, 
the differences among the studies may be explained, at least 
in part, by differences in these parameters. Also, as Suet al. 
(13) point out, the requirements for anergy may be differ- 
ent from those for cell death. For example, the study dem- 
onstrating fratricide was carried out at 107-fold higher pep- 
tide concentration than required for 50% tysis of targets, 
whereas the anergy induction occurred in a peptide con- 
centration range similar to that required for target sensitiza- 
tion (Fig. l A). Thus, high dose inhibition may be playing 
a role in some studies and not others, invoking a mecha- 
nism different from that of free peptide at lower concentra- 
tions. 
To investigate fratricide as a mechanism in our system, 
we used two distract and non-cross-reactive CD8 + CTL 
lines, LINE-ItIB and LINE-MN, specific for the homolo- 
gous peptides 1-10 (18IIIB) or MNT10 (18MN), respec- 
tively, and restricted by the same class I MHC molecule, 
H-2D a. We did not detect any ;inhibition when the LINE- 
IIIB cells were prepulsed or mixed with soluble 18MN or 
MNTI0  and cocultured with L INE-MN cells that should 
kill such peptide-pulsed LINE-IIIB cells if the mechanism 
were fratricide, and vice versa in the reciprocal combina- 
taon. Moreover, when half the CTL line cells were pulsed 
with the peptide for which they were specific and cocul- 
tured with the other half, the cytolytic activity of the un- 
pulsed cells was not inhibited. These results exclude a clas- 
sic veto mechanism (11, 21-24). In addition, we confirmed 
that 51Cr-labeled 1-10--pulsed CD8 § CTL are not killed by 
LINE-IIIB, consistent with resistance of CTL to lysis (2-4). 
We conclude that fratricide is not the mechanism of inhibi- 
tion in our system. 
Furthermore, we have shown that 1-10-treated CTL can 
be restored to almost 80% of their original activity by re- 
stimulation 2 d after peptide treatment. This result and the 
absence of obvious DNA ladders in the treated CTL also 
strongly suggest that the principal mechanism is not suicide. 
Taken together, these results uggest that the major mecha- 
nism of inhibition, under our conditions, is transient self- 
inactivation (anergy or paralysis), not cell death. This inter- 
pretation is consistent with the downregulation of receptors 
we observed. However, it should be noted that the differ- 
ence between cell death and anergy may depend on the 
state of the CTL in the conditions of the experiment, such 
as their bcl-2 levels, so that either outcome may be possible 
under different circumstances, ven when the signaling mech- 
anism is the same. 
The effect of peptide length may be an important vari- 
able not analyzed in previous tudies that may explain some 
differences in results. Here we show that longer peptides, 
such as 18IIIB, need processing by protease(s) present in 
FCS that can be inhibited by specific inhibitors uch as cap- 
topril (26); thus, only the optimal-sized peptide, such as 1-10, 
caused rapid and strong inhibition of CTL activity, whereas 
it takes >2 h for the 15-residue peptide 18IIIB to inhibit. 
Therefore, some discrepancies between studies may be due 
to use of longer peptides to analyze the inhibitory mecha- 
nism. For example, the difference between the FACS ~ 
analysas data of Robbins and McMichael (10) and ours may 
come from the length of the peptide used in the assay, in 
that they demonstrated downmodulation of CD8 but not 
of IL-2 receptor or TCR in the presence of free 13-mer 
peptide from influenza nucleoprotein, which required 10 h 
for inhibition and was more variable, as we have seen for 
the 15-mer 18IIIB. 
To better understand the minimal signaling requirements 
for free peptide to inhibit, we also studied the efficacy of 
other APC in inducing the inhibition. First, we found that 
BALB/c.3T3 fibroblasts expressing 1-10, either externally 
pulsed or internally synthesized, di  not inhibit the activity 
of specific CD8 § CTL. Second, 1-10-pulsed Dd-expressing 
whole spleen ceils from B10.A mice, containing a variety 
of APC, did not affect the CTL activity when the B10.A 
cells were removed before the SICr-release assay to avoid 
cold-target blocking. (Since the spleen ceils also contain T 
cells that could act as veto cells, these results also help to 
exclude a classic veto cell mechanism [11, 21-24].) Third, 
we found that presentation of 1-10 by the BALB/c CD4 + 
Th cell line, HT-4, did not inhibit CD8 + CTL, except by 
cold-target inhibition, which could be eliminated by de- 










Published March 1, 1996
pletion of  the CD4 + cells. In contrast, CTL line cells that 
could not be killed when pulsed with peptide also did not 
act as cold targets and did not inhibit. T ime-dependent 
morphological changes in isolated CTL with free peptide 
(data not shown), similar to the morphological change ob- 
served by Walden and Eisen (8), if  indicative of  the same 
phenomenon, also exclude cold target inhibition by other 
CTL and suggest action at the single cell level. Thus, pre- 
sentation of  peptide by any other cell does not mimic the 
effect of  free peptide. 
Nevertheless, the data indicate that the free peptide does 
not act in the free state, but must be presented by a class I 
MHC molecule. Captopril abrogation of  inhibition by 
18IIIB but not 1-10 suggests that the inhibition requires 
binding of  the minimal peptide to the class I MHC mole- 
cule on the CD8 + CTL. This conclusion is supported by 
partial blocking of  inhibition by pretreatment of CTL with 
anti-D d (data not shown) and by the fact that a noninhibi- 
tory, nonantagonistic 1-10 variant with a single substitution 
at a key TCl~-interacting site competed against he inhibi- 
tory activity of  the unmodified 1-10. The modified peptide 
could not compete for binding to the TCP,  because it had 
neither agonist nor antagonist activity despite binding to 
D a. Thus, competit ion must be for binding to the MHC 
molecule, a further indication that free peptide has to bind 
to the MHC molecule to inhibit. Vitiello et al. (7) similarly 
concluded that the peptide must be presented on the MHC 
molecule of  the CTL itself from experiments using D b- 
restricted influenza nucleoprotein-specific CTL derived 
from chimeric mice in which the CTL were of  different 
genetic origin ot expressing D b. However, the fact that 
CTL -CTL  presentation of  peptide did not produce cold- 
target inhibition, and the inability of  this mechanism to ex- 
plain the downregulation of  multiple surface molecules on 
the CTL, make cold-target inhibition of  a single CTL by 
its own MHC molecules presenting peptide (7) unlikely. 
Taken together, these results, which demonstrate a require- 
ment for binding to the class I MHC molecule but exclude 
presentation on other cells, indicate that the free peptide 
must be presented on the CTL themselves to induce spe- 
cific CD8 + CTL inhibition. 
How then does presentation of the peptide on the CTL's 
own MHC molecules differ from presentation on the same 
MHC molecule of  another cell? The experiments in which 
CTL of  different specificity but similar MHC restriction, 
pulsed with each other's peptide, can inhibit each other 
(Fig. 5), in contrast o the case in which the peptide for 
only one of  the CTL is present (Fig. 4), show that the min- 
imal requirement for inhibition is simultaneous occupancy 
of  the TCI< and MHC molecule on the CTL. This dou- 
ble-pulsing experiment of  Fig. 5 creates a situation in 
which the CTL cannot see the peptide on their own MHC 
molecules, but must see it on another CTL, and yet each 
CTL has both its MHC molecules and TCP,  engaged (Fig. 
8 B). It allows us to conclude that such simultaneous dual 
engagement of  MHC and TCP,. on the same cell is re- 
quired. In the normal circumstance with a single CTL line 
and a single peptide, this situation can occur between pairs 
of  the same CTL at high density incubated with free pep- 
tide (Fig. 8 C), as well as on isolated single cells (Fig. 8 A). 
When cells of  the same clone are not together at high den- 
sity, as may often be the case in nature, the single-cell 
mechanism may be the only one available. Presentation i  
the same cell is possible because the cell surface is not 
smoothly convex, but has many projections and invagina- 
tions, and independent evidence for such a functional in- 
teraction has been obtained (Koenig, S., personal commu- 
nication). If  a mixture of  peptides and CTL specific for 
them occurs, as during lysis ofviral ly infected cells, the sit- 
uation in Fig. 8 B, as created in the experiment shown in 
Fig. 5, may also arise. Thus, our results suggest hat the 
most hkely mechanism of  this inhibition may be signal 
transduction within the CTL  by having its TCP,. ligated to 
its own MHC molecules in cis or in a reciprocal interaction 
with a sister cell's TCP,  and MHC molecules in trans, re- 
suiting in reversible downregulation of  surface molecules. 
Figure 8. Model of the self-veto or dual engagement mechanism of 
CTL inactivation by free peptide. The data indicate that the minimal re- 
quirements for free peptide to inactivate CTL are simultaneous occ -
pancy of the class I MHC molecule and the TCP- on the same CTL. This 
may occur in an isolated cell when the TCP, of a cell binds the p ptide- 
MHC complex formed on the same cell (A). Because the cell surface is 
not smooth, but has many projections and invaginations, TCP,. and MHC 
molecules on the same cell can easily come into contact. Alternatively, 
the same simultaneous engagement of TCP, and MHC may occur be- 
tween two cells. In the experiment shown in Fig. 5, in which two non- 
cross-reactive CTL lines were pulsed with ach ot er's peptide, it can oc- 
cur only when two cells of opposite types come together and recognize 
their peptides on the other cell's MHC molecules (B). However, in the 
simpler situation with a single CTL and a single free peptide, two sister 
cells each binding the peptide may inactivate each other (C). Whether the 
upper single-cell or the lower two-cell mechanism predominates may de- 
pend on cell density. 
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Simultaneous signaling though the TCR and MHC mole- 
cule on the same T cell appears to inhibit. 
Recendy, signaling though MHC class I, such as by 
cross-linking with specific antibodies, has been shown to 
regulate signal transduction though the TCR.--CD3 com- 
plex and can lead to inhibition of cellular function (43), in- 
cluding cytotoxicity (44), perhaps by prolonging the dura- 
tion ofa CD3-induced elevation in intracellular Ca 2+ (45). 
Sustained increases in intracellular Ca 2§ can often lead to 
unresponsiveness in CTL (46); consequendy, MHC class I 
modification of TCR-CD3 signals may represent another 
mechanism for the induction of anergy. T cell signaling 
through the class I molecule does not depend on the MHC 
cytoplasmic domain (47), but instead requires association of 
class I protein with other cell surface molecules (48, 49). 
Most studies of MHC class I signal transduction and regula- 
tion of CTL effector function have involved the use of an- 
tibodies as an MHC cross-linking agent. In our system, en- 
gagement of MHC class I-peptide complex on a CTL 
instead by a TCR may lead to anergy via MHC class I reg- 
ulation of TCR signaling events. This mechanism of an- 
ergy induction appears to be distinct from that of TCR 
triggering in the absence ofa costimulatory signal (19, 50). 
The requirement for simultaneous signaling through the 
TCR and MHC molecule on the same CTL is reminiscent 
of the molecular mechanism proposed for the veto phe- 
nomenon (23, 24). The TCR of the CTL being vetoed 
must bind the MHC molecules of the veto cell, and the 
CD8 molecule of the veto cell binds the o~3 domain of class 
I MHC molecules of the CTL. Thus, the CTL has both its 
TCIk and its class I MHC molecules engaged. The dual 
engagement permitted by free peptide may be a stronger 
signal through the MHC molecule, involving the interac- 
tion of TCR. rather than CD8 with the peptide-MHC 
complex, and thus may account for inhibition of T cell 
clones resistant o classic veto. Nevertheless, the require- 
ment for concurrent engagement of both molecules is a 
clear parallel. We are not aware of any previous connection 
made between free peptide inhibition and the veto phe- 
nomenon, but on the basis of the results presented here, we 
propose that free peptide inhibition of CTL activity is actu- 
ally a process of self-veto. 
There are a number of potential mechanisms of inhibi- 
tion of virus-specific CTL in HIV-l- infected patients. We 
have observed a similar inhibitory effect of free peptide in 
vivo in primed animals (Takahashi, H. and Y. Nakagawa, 
unpublished observations), and Walden and Eisen (8) also 
observed a similar loss of CTL activity in spleen cells of 
primed animals after injection of an OVA peptide. Perhaps 
when vitally infected cells are lysed and the digested intra- 
cellular proteins released into the environment of the T 
cell, anergy may be induced and clearance of the virus from 
other infected cells prevented. Thus, the self-veto mecha- 
nism shown here may contribute to inactivation of virus- 
specific CTL in vivo and virus persistence, and, conversely, 
restoration of such inactivated CTL may prevent virus 
spread and disease progression. 
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